Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qitao Huayu formula for hypercoagulable state after total knee arthroplasty
ChiCTR2300072495Phase 4Not yet recruiting
- Sponsor
- Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rivaroxaban in Hypercoagulability (2 arms), sponsored by Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. Primary endpoint: D-dimer. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
Hypercoagulability
Beyond the preview
Go deeper on ChiCTR2300072495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072495.